CMPS logo

CMPS
COMPASS Pathways

8,141
Mkt Cap
$519.37M
Volume
2.75M
52W High
$8.90
52W Low
$2.25
PE Ratio
-2.02
CMPS Fundamentals
Price
$5.41
Prev Close
$5.73
Open
$5.71
50D MA
$6.89
Beta
1.35
Avg. Volume
5M
EPS (Annual)
-$2.30
P/B
13.82
Rev/Employee
$0.00
$121.81
Loading...
Loading...
News
all
press releases
Compass Pathways Eyes Rolling FDA Filing for COMP360, Preps TRD Launch Ahead of Q3 Data
Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch preparation for its investigational psilocybin therapy, COMP360, during a recent fireside chat. Chief Executive Officer Kabir Nath and Chief Commercial Officer Lori Englebert discuss...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Short Interest Update
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) was the target of a significant increase in short interest in February. As of February 27th, there was short interest totaling...
MarketBeat·5d ago
News Placeholder
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the...
Business Wire·10d ago
News Placeholder
Compass Pathways (NASDAQ:CMPS) Trading Down 6.3% - What's Next?
Compass Pathways (NASDAQ:CMPS) Trading Down 6.3% - Here's What Happened...
MarketBeat·11d ago
News Placeholder
Compass Pathways (NASDAQ:CMPS) Trading 8.8% Higher - What's Next?
Compass Pathways (NASDAQ:CMPS) Stock Price Up 8.8% - Time to Buy...
MarketBeat·12d ago
News Placeholder
Jefferies Financial Group Inc. Invests $7.89 Million in Compass Pathways PLC Sponsored ADR $CMPS
Jefferies Financial Group Inc. purchased a new stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) during the 3rd quarter, according to its most recent Form 13F filing...
MarketBeat·12d ago
News Placeholder
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...
PR Newswire·13d ago
News Placeholder
Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference
Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant...
MarketBeat·14d ago
News Placeholder
HC Wainwright Lifts Earnings Estimates for Compass Pathways
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Research analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Compass Pathways in a report issued on Monday...
MarketBeat·17d ago
News Placeholder
Propel Bio Management LLC Makes New $2.92 Million Investment in Compass Pathways PLC Sponsored ADR $CMPS
Propel Bio Management LLC acquired a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the...
MarketBeat·17d ago
<
1
2
...
>

Latest CMPS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.